Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Apixaban
Drug ID BADD_D00151
Description Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].
Indications and Usage Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence[Label,A177565,A6897].
Marketing Status approved
ATC Code B01AF02
DrugBank ID DB06605
KEGG ID D03213
MeSH ID C522181
PubChem ID 10182969
TTD Drug ID D0I5HF
NDC Product Code 0003-0893; 52048-0420; 69037-0023; 76397-007; 15308-1221; 24196-190; 58032-2028; 66174-0091; 50193-0893; 65372-1196; 65727-081; 0003-3764; 55154-0612; 59651-051; 70366-001; 14445-149; 12783-0893; 12783-0894; 17381-026; 42765-025; 42816-0894; 58623-0137; 63850-8085; 65129-1344; 66039-925; 66651-921; 69989-0006; 63629-7747; 12658-0440; 53869-0893; 73377-191; 55154-0613; 70518-1861; 71610-662; 67835-0015; 75945-060; 76397-010; 50090-6454; 82982-054; 14501-0089; 16436-0113; 65129-1465; 63629-8432; 14445-014; 53747-062; 53869-0894; 63415-0520; 65015-897; 76072-1017; 14445-150; 42816-0893; 0003-0894; 55111-980; 50090-6451
UNII 3Z9Y7UWC1J
Synonyms apixaban | Eliquis | BMS 562247 | BMS562247 | BMS-562247-01 | BMS-562247
Chemical Information
Molecular Formula C25H25N5O4
CAS Registry Number 503612-47-3
SMILES COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Mesenteric artery thrombosis07.15.02.008; 24.01.08.0030.000043%-
Microcytic anaemia01.03.02.0080.000239%-
Mitral valve incompetence02.07.01.0020.000195%-
Monoparesis17.01.04.0110.000065%-
Motor neurone disease17.05.05.0020.000043%-
Mouth haemorrhage07.05.02.001; 24.07.02.0140.000911%
Muscle haemorrhage12.01.07.016; 15.05.03.017; 24.07.01.0370.000768%-
Myasthenia gravis10.04.05.001; 15.05.08.001; 17.05.04.0010.000130%
Nasal inflammation22.04.04.0020.000148%-
Nasal polyps16.38.01.001; 22.04.03.0100.000065%-
Nasal septum deviation22.04.03.0190.000043%-
Nasal septum perforation22.04.03.0030.000065%-
Nausea07.01.07.001--
Necrosis08.03.03.001; 24.04.02.0060.000260%-
Neoplasm16.16.02.0010.000551%-
Neoplasm malignant16.16.01.0010.003775%-
Nephritis20.05.02.0010.000043%-
Nephropathy20.05.03.0010.000291%-
Nervous system disorder17.02.10.001---
Neuropathy peripheral17.09.03.003---
Normochromic normocytic anaemia01.03.02.0050.000108%-
Oesophageal haemorrhage07.12.01.002; 24.07.02.0210.000130%
Oesophageal obstruction07.13.02.0020.000043%
Oesophageal stenosis07.13.02.0010.000065%
Oesophageal ulcer07.04.05.0020.000204%
Oesophageal varices haemorrhage07.12.01.003; 09.01.06.004; 24.07.02.0220.000174%
Oesophagitis07.08.05.0010.000282%
On and off phenomenon17.01.05.0040.000065%-
Ophthalmoplegia06.05.02.003; 17.17.02.0050.000043%-
Optic ischaemic neuropathy06.07.03.001; 17.04.05.006; 24.04.10.0010.000087%-
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 26 Pages